Luye Pharma Group Ltd. (Luye Pharma) reported no changes to its equity structure for the month ended 31 March 2026, according to its monthly return filed with Hong Kong Exchanges and Clearing Limited.

The company’s authorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.02 each, translating into total authorised capital of USD 200.00 million. Issued shares (excluding treasury shares) were unchanged at 3.99 billion. Luye Pharma held no treasury shares at month-end.

Public-float requirements were met, with at least 25% of the issued ordinary shares held by the public as stipulated under Main Board Rule 13.32B.

Outstanding convertibles consist of USD 180.00 million in listed convertible bonds (stock code 05818) carrying a conversion price of HKD 4.88 per share. No conversions occurred during March, leaving the potential issuance capacity at 288.79 million new ordinary shares—equivalent to about 7.23% of current shares in issue.

There were no share options, warrants, other equity instruments or Hong Kong Depositary Receipts in effect, and the company confirmed full compliance with all Listing Rules and regulatory requirements for the period under review.